Analysts say the deal, which would give Biogen full control over the drug Zurzuvae, could be a smart financial move. Yet it's ...

The proposed deal comes soon after Sage implemented a restructuring plan to focus on Zurzuvae’s launch in postpartum ...

Sage Therapeutics' financials indicate a need for additional funding in 2025, risking dilution and further financial ...

Biogen is looking to augment growth by hunting for biotechs with drugs in mid- and late-stage clinical development.

Truist keeps a Hold rating on Sage Therapeutics (SAGE) after Zurzurvae’s commercial partner Biogen (BIIB) disclosed an unsolicited proposal to ...

Sage stock rose 35% to $7.51 in premarket trading Monday; it closed at $5.55 on Friday. Biogen shares dipped 0.5% to $48.01.

Biogen’s proposed acquisition comes after two difficult years of regulatory and clinical challenges, during which shares of ...

The $7.22-per-share deal for 89.8% of Sage is a 30% premium on the company's share price on Friday and is estimated by ...

Biogen proposes acquiring Sage Therapeutics for $7.22 per share, as analysts highlight the strategic value of Zurzuvae's ...

Today's sure has SAGE on track for its largest single-day percentage gain since January 2019. Though further removed from ...

As the first and only approved drug for post-partum depression, the offer undervalues Zurzuvae, the analyst tells investors in a research note. The firm thinks the drug is off to a slow ...

The two biotechnology companies have worked together over the past four years on a mood-stabilizing medicine known as Zurzuvae. They split research costs and, after the medicine got approved as a ...